Please ensure Javascript is enabled for purposes of website accessibility

Why Supernus Pharmaceuticals, Inc. Is Falling Today

By Brian Feroldi - Updated Aug 8, 2018 at 3:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares sell off after the company posts mixed second-quarter results. Here's what investors need to know.

What happened

Shares of Supernus Pharmaceuticals (SUPN 3.46%), a profitable commercial-stage biopharma focused on diseases of the central nervous system, dropped 11% as of 2:35 p.m. EDT on Wednesday. The selling is attributable to the release of the company's mixed second-quarter results.

So what

Here's an overview of the headline numbers from Supernus' second quarter:

  • Revenue increased 31% to $99.5 million. The gain was driven by a 36% jump in sales of the epilepsy drug Trokendi XR and a 19% rise in Oxtellar XR. By contrast, Wall Street was looking for $101 million in total revenue.
  • GAAP earnings per share jumped 78% to $0.57. This result was far higher than market watchers' prediction of just $0.43.
Light-green dollar signs in drug packets

Image source: Getty Images.

Management also took the opportunity to adjust its financial guidance for the full year:

  • Sales are expected to land between $385 million and $400 million. This is an increase over its prior guidance range of $375 million to $400 million in total sales.
  • Operating earnings are forecast to come between $130 million and $140 million. This is a $5 million boost over its previous range.

Despite posting good-looking results and modestly boosting guidance, traders appear to be squarely focused on the slight miss on the top line. 

Now what

Supernus has been a red-hot stock for many years -- shares are up 621% since 2013 -- so it isn't too surprising to see it taking a step back in light of the mixed quarterly results. However, revenue and earnings growth of 31% and 78%, respectively, are very strong in absolute terms, so I think that long-term investors should continue to feel good about this company's chances moving forward.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Supernus Pharmaceuticals, Inc. Stock Quote
Supernus Pharmaceuticals, Inc.
SUPN
$28.40 (3.46%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.